AFFILIATE HANDBOOK

Everything the program is, in one page.

How to publish well, stay inside the line, and get paid on time. Written by the two people who read every piece of content you produce.

v2.0 · Maintained by Logan P. and Logan D. · Revised 19 August 2026



01 A welcome from us.

Logan P. and Logan D. here, both of us, equally. If you are reading this you have been approved, or you are about to be. Either way, thank you, and we do not mean that as a formality. Kodiac is two people. Affiliates are not a marketing channel to us, they are most of how anyone hears about this company at all.

This handbook exists because the alternative is what most programs in this category do: hand you a code and a banner image and wish you luck. The result is content that looks like an ad, gets ignored, and embarrasses everyone involved. We would rather give you the actual playbook. What works, why it works, what gets an affiliate paused, and the exact templates we have seen convert.

Read it once end to end. After that treat it as reference. Section 05 is the one that matters most and the one we will hold you to, so if you only reread one thing, reread that. If anything here is unclear or contradicts itself, write to either of us and whoever sees it first fixes it in the next revision.

We split the program down the middle. Both of us read every email, both of us approve every applicant, both of us write to you when something changes. If one of us is heads-down on a batch run and slow to reply, the other will not be.

Logan P.

Co-founder

loganp@kodiac.bio

Logan D.

Co-founder

logand@kodiac.bio


02 Our promise to you.

These are commitments, not policies. If we break one you can hold us to it in writing, quoting this page.

  1. We pay above market and we do not move your rate down. The rate you are approved at is a floor. We can raise it. We will not lower it without 60 days of written notice and a real conversation about why. If we add tiers, you climb the new ladder rather than being reset onto it.
  2. Net 30 means Net 30. Any calendar month is paid by the 30th of the following month. If we are going to be late you hear why before the deadline, not after.
  3. We do not claw back commission on legitimate orders. Once an order ships and the customer is satisfied, your commission is locked. We reverse only for refunds, chargebacks, or orders we determine to be self-purchased or fraudulent, and we tell you in writing when we do.
  4. Your code is yours. We do not rotate it, retire it while you are active, or hand it to somebody else.
  5. We reply within two business days. If you do not hear back, assume the mail went missing and resend. Both founders are on the affiliate inbox.
  6. We do not poach your audience. Customers who arrive on your code are tagged as yours in our system. We do not run retention campaigns designed to route them away from you, and we do not bid on your name or your branded terms.
  7. We tell you the truth about the product. If a batch does not meet spec you hear it from us before you hear it from a customer. If we discontinue a compound you have published about, we email you so you can update your content rather than leaving it pointing at a dead page.

03 What an affiliate actually does.

If you have done affiliate work elsewhere this section will surprise you. We are not asking for what other compound brands ask for.

You are not a salesperson.

You are a writer, podcaster, lab director or community lead who already produces work an audience trusts. Affiliating with Kodiac does not change what you make. It changes which supplier you point at when somebody asks where the material in the paper you just spent twenty minutes explaining actually comes from.

A normal month.

  • Publish on a Kodiac compound when it fits. There is no quota. Strong affiliates tend to land two to six relevant pieces a month, but volume is not the metric we care about and we have never paused anyone for being quiet.
  • Put your code where it belongs. Pinned comment, description, show notes, link in bio. Section 09 covers exactly where, per platform.
  • Disclose, once per piece, in the content itself. FTC requirement, and also just correct.
  • Stay in research framing. Section 05. This is the one with teeth.
  • Send signal back. If your audience keeps asking for something we do not stock, tell us. If a customer reports a problem, forward it. This is genuinely useful to us and it is how the catalog gets decided.

What doing well looks like.

The affiliates we pay the most are not the ones with the largest audiences. They are the ones whose audiences trust their pharmacology coverage enough to click through, place a real order, and stay. A 5,000-reader pharmacology newsletter beats a 500,000-follower wellness account in this program every time, because the audience match is right and the wellness framing is the exact framing we cannot use.

You are doing well when the same customers reorder and tell us, unprompted, that they found us through you.


04 The pay structure, in full.

TierRateTrigger
Starting20%Every approved affiliate, from your first attributed order.
Established25%5,000 dollars of attributed revenue inside a calendar month.
Principal30%20,000 dollars of attributed revenue inside a calendar month.

How a tier applies.

The tier rate applies to the entire calendar month you triggered it in, not from the moment of trigger forward. If your code clears the Established threshold on the 28th, every attributed order back to the 1st of that month is paid at 25 percent. The same logic applies to Principal.

Tiers reset monthly. They are not lifetime. That is what keeps the arithmetic simple enough for you to verify it yourself, which matters more to us than a ladder that only ever ratchets.

What counts, and the arithmetic.

Attributed revenue is the merchandise subtotal, before shipping and tax, on every paid order where the customer used your code. Your customer’s 10 percent discount comes off before your commission is calculated, so your rate applies to the discounted subtotal. We would rather state that plainly here than let you discover it from a payout.

Customer order subtotal200.00
Customer discount, 10 percent20.00 off, subtotal becomes 180.00
You earn at Starting, 20 percent36.00
You earn at Established, 25 percent45.00
You earn at Principal, 30 percent54.00

What does not count.

  • Self-purchases. Orders placed by you, by anyone at your household billing address, or by your business entity.
  • Refunded or charged-back orders. Commission reverses.
  • Wholesale and institutional contracts negotiated separately by us.
  • Orders shipping somewhere we cannot legally serve. Those are voided at checkout, so they should never appear, but if one does it is excluded.

Payout cadence.

Books close on the last day of each calendar month, UTC. The month total settles once the final order has cleared. Payouts go out by the 30th of the following month, by the method you chose at onboarding. The minimum payout is 50 dollars and anything below it rolls into the next month rather than being forfeited.

When to ask for something different.

If you are running an institutional procurement conversation, a large bulk order, or a content sponsorship that does not fit this shape, write to us. We will do flat fees, retainer plus commission, or one-off payments for work we commission directly. The structure above is the floor of what is possible, not the ceiling.


05 The line, and a phrasebook for staying on it.

This is the section that gets affiliates paused, and the only one where we have no discretion to be relaxed. Read it twice.

Kodiac supplies research materials. Not supplements, not therapeutics, not anything intended for human or veterinary use. That is not a disclaimer we bolt on, it is what the product actually is and what our documentation supports. Everything you publish about us has to be consistent with it.

The reason this is your problem and not only ours: under the FTC Endorsement Guides an advertiser can be held liable for claims made by its endorsers, and an FDA view of intended use is built from the whole body of evidence around a product, including how the people selling it talk about it. Your content is part of our record. That is why we test on it before approving anyone.

The single rule, if you remember nothing else. Report what the literature found and what the documentation shows. Never describe, recommend, or imply administration to a person, including yourself. “A 2024 trial reported X in participants” is reporting. “I ran this for six weeks” is administration, no matter how it is framed, and no matter how many times the word research appears next to it.

What you can publish.

  • Mechanism. What a compound binds, what it modulates, which pathways it touches, how selective it is.
  • The literature, in full. What studies found, in what model, at what sample size, with what limitations. Preclinical and clinical both. Including dosing as reported in a study, attributed to that study, as a fact about the study.
  • What is unresolved. Contradictory results, underpowered trials, the experiment nobody has run. This is the most valuable thing you can publish and almost nobody does it.
  • Analytical facts about the material. Purity, the assay used, the lot, what the COA says, who ran it. These are documented properties of a substance, they are not claims about a person, and they are the strongest thing you can say about Kodiac specifically.
  • Comparisons within a class. Half-life, potency, receptor selectivity, stability, cost per milligram.

What you cannot publish.

  • Any account of personal administration. Yours or anyone else’s. This includes results, logs, before-and-after, bloodwork framed as an outcome of taking something, and any narrative in the first person about running a compound. Calling it a protocol does not convert it into research.
  • Dosing guidance for a person. You may cite what a study administered. You may not translate that into what a reader should take, convert it to a human-equivalent dose, or answer “how much should I use” in any format, including a reply in your own comments.
  • Therapeutic, curative or preventive claims. “Reduces anxiety”, “heals tendon”, “reverses ageing”. These are claims about people.
  • Supplement or wellness positioning. Stacks, regimens, “best for sleep”, cycle advice, anything that frames the catalog as a consumer product line.
  • Route of administration advice. Reconstitution instructions, injection technique, storage of a prepared solution. Kodiac deliberately publishes none of this and neither do you.
  • Implying regulatory approval. Nothing here is FDA approved for anything, and saying a compound is “clinically proven” implies otherwise.

The phrasebook.

Most violations are not people trying to break a rule. They are ordinary sentences that carry an implication their author did not notice. The left column is what people write. The right column says the same thing and is fine.

Do not writeWrite instead
Semax lowers anxiety.Semax has been studied for anxiolytic-like effects; the 2011 rodent work is where most of that comes from, and human data is thin.
I have been running BPC-157 for six weeks.The BPC-157 literature is mostly rodent tendon and gut models. Here is what the strongest three papers actually measured.
Start at 250 micrograms a day.The trial dosed 250 micrograms daily in participants. Whether that translates anywhere else is exactly the open question.
This is the best peptide for recovery.Within this class it is the one with the most published tissue-repair data, which is not the same as the most effective.
Great for stacking with GHK-Cu.The two are studied in overlapping tissue-repair contexts. No study I am aware of has tested them together, which is worth saying out loud.
Clinically proven and lab tested.Not approved for any use. What Kodiac documents is identity and purity: HPLC, mass spec and NMR per lot, published by lot number.
Kodiac’s is the purest on the market.Kodiac publishes a per-lot COA you can pull up by lot number before you buy. Most vendors in this category publish nothing you can tie to the vial you received.

Answering your own comments.

The comments are where most of this goes wrong, because the content was careful and the reply was casual. Somebody will ask what to take and how much. The correct reply, every time, is that you do not give dosing guidance because the material is supplied for research use only, and then point at the paper. Copy this if it helps:

I do not give dosing or use guidance. This is research-use-only material and I am not in a position to advise anyone on taking it. What I can tell you is what the study did: [study, year, model, what was administered to what]. What that means outside those conditions is not established.

The voice.

Read a few of the monographs on kodiac.bio and you will pick it up. Technical, sober, citation first, allergic to hype. We assume the reader is intelligent and has a search engine. We frame uncertainty as uncertainty. We do not use exclamation points.

You do not have to imitate us, and you should not. Your voice is why your audience listens. But content that reads as wellness influencer copy will underperform in this niche and bring the wrong people to our checkout, which helps neither of us.

Things we will never ask you to do.

  • Pretend to be a customer when you are not.
  • Hide the affiliate relationship.
  • Run negative content about competitors. Pick us on merit or do not pick us.
  • Use stock imagery of patients, clinicians or anyone appearing to consume a product.
  • Soften a real problem with a batch.

06 FTC disclosure, and the pre-publish checklist.

Every piece where you mention Kodiac or your code needs a disclosure. This is enforced law, not a tone preference.

The standard is that a reasonable person cannot miss it. That means inside the content, not in a bio, not behind a “more” truncation, and not only in a pinned comment. Three formats follow; use the one that fits the surface.

Short form, for a caption or a post.

Affiliate: I earn a commission if you order through my code KODIAC-YOURNAME. The discount goes to you.

Long form, for a description, article or newsletter.

Disclosure: I have an affiliate relationship with Kodiac biolabs. If you use the code KODIAC-YOURNAME at kodiac.bio you get 10 percent off and I earn a commission. This does not affect what I publish, which compounds I cover, or my willingness to say when something is wrong with the product. Kodiac does not review or approve my content before it goes out.

Spoken, for video or audio.

Quick note before we start. I have an affiliate relationship with Kodiac, so if you use my code at their site I earn a commission. They have no say in what I cover or how I cover it.

The pre-publish checklist.

Six questions. If any answer is wrong, fix it before it goes out rather than after. This takes under a minute once it is habit, and it is the entire difference between an affiliate we never have to write to and one we do.

  1. Is the disclosure inside the content, early, and impossible to miss without expanding anything?
  2. Does any sentence describe a person taking the compound, including me?
  3. Is every dose figure attributed to a specific study, and phrased as what that study did rather than what anyone should do?
  4. Would a stranger reading only the title and thumbnail think this is a supplement recommendation?
  5. Have I said at least one honest thing about what the evidence does not show?
  6. Is my code correct, live, and pointing at kodiac.bio?

07 Video.

Video drives most of the attributed revenue in this program. If you skim anything, do not skim this.

Titles that work.

Treat the title as a promise about what the viewer will learn. The compound is the hook; we are the supplier reference, and a title about Kodiac converts worse than a title about the science.

FormulaExample
Compound plus mechanismTropisetron: a 5-HT3 antagonist with unexpected cognitive data
Compound against compoundSemax against Selank: what the literature actually shows
Paper reviewReading the 2024 BPC-157 oral bioavailability paper properly
State of the evidenceWhat the evidence on tissue-repair peptides does and does not support
Analytical angleWhat a peptide COA actually tells you, and what it does not

Titles to avoid.

  • “INSANE results from [compound]” reads as wellness clickbait and destroys credibility with the audience that actually buys.
  • “I tried [compound] for 30 days” is a compliance violation in the title alone. So is any variant that keeps the personal-administration frame and adds the word research. There is no compliant version of this format; pick a different one.
  • “[Compound]: the best supplement of 2026” positions the catalog as supplements.
  • “Kodiac review” buries the science and converts poorly.

Structure for an 8 to 14 minute piece.

  1. 0:00 to 0:15, the hook. A counterintuitive finding, a concrete analytical result, or a question your audience actually asked you this week.
  2. 0:15 to 0:45, disclosure and frame. Spoken disclosure, then what the viewer will learn, then the research framing stated once so it governs everything after it.
  3. 0:45 to 3:00, mechanism. What it binds and what that implies. A diagram earns its place here.
  4. 3:00 to 7:00, evidence. Two to four papers. Name the journal, the year, the model and the sample size. Show the figure. Say what is weak.
  5. 7:00 to 10:00, context. Half-life, stability, what to compare it against in the same class.
  6. 10:00 to 12:00, the supplier note. Why you point at Kodiac for this compound: the per-lot COA, the lot verification, the price relative to the class. Read the code aloud and hold it on screen for at least eight seconds.
  7. Close. The open question you would want answered, and an invitation to argue with you about it.

The pinned comment.

The highest-converting placement on YouTube. Pin it within five minutes of publishing. Note that it supplements the in-content disclosure and never replaces it.

Disclosure: affiliate. Code KODIAC-YOURNAME gets you 10 percent off at kodiac.bio.

Papers cited, in order: 1. Author, year, journal, DOI. 2. Author, year, journal, DOI. 3. Author, year, journal, DOI.

B-roll.

  • Product photography from our asset library on a clean surface. Do not stage a laboratory you do not work in.
  • Receptor and pathway diagrams. Cite the source if you traced one from a paper.
  • The HPLC trace from a real COA. Ask us and we will send a cleaner export.
  • Hand-drawn structures on paper. These perform surprisingly well and cost nothing.
  • Never: syringes, vials being drawn, anything depicting preparation or administration.

08 Three sample scripts.

Not for copy and paste. They show structure, voice and disclosure working together, and every one of them stays in third-person literature framing on purpose.

Script 1. Mechanism deep dive, roughly 8 minutes.

[0:00 hook] Tropisetron has been a clinical antiemetic for thirty years. The part almost nobody discusses is a small body of work suggesting 5-HT3 antagonism has second-order effects on attention and procedural learning. I want to walk through what that literature actually says, and where it stops.

[0:25 disclosure] Disclosure first. I have an affiliate relationship with Kodiac biolabs, whose research-grade tropisetron I reference in these videos. Code is in the description. They have no say in what I cover.

[0:45 frame] Three things today. What 5-HT3 antagonism is at the receptor. The three papers most relevant to the cognitive question. And what I would want studied next. This is research material and this is a literature discussion, not use guidance.

[1:00 mechanism] 5-HT3 is the only ionotropic serotonin receptor. Unlike the GPCR-family 5-HT receptors it is a ligand-gated cation channel, so it operates on a millisecond timescale and modulates fast synaptic transmission rather than slow second-messenger signalling. That distinction is doing a lot of work in the cognitive story.

[3:00 evidence] Paper one, Macor and colleagues, 2001, in the Journal of Pharmacology and Experimental Therapeutics. 5-HT3 antagonism enhanced acetylcholine release in rat cortex. The effect was consistent but the sample was 8 per condition, which is small, and it is a rodent cortex measurement rather than a behavioural endpoint. Take the direction seriously and the magnitude lightly.

[7:00 supplier note] On sourcing. The reason I point at Kodiac for tropisetron specifically is the per-lot analysis. Every batch ships with HPLC, mass spec and NMR documentation published against the lot number, so you can check the specific material before you buy it. For a compound where an impurity profile would compromise exactly the receptor selectivity I just spent seven minutes describing, that is the thing worth caring about. Code KODIAC-YOURNAME at kodiac.bio, 10 percent off.

[7:45 close] The open question is dose-response on the cognitive endpoints. None of the existing work titrates. If somebody has run that, put it in the comments; I read all of them.

Script 2. Paper review, roughly 5 minutes.

[Hook] A paper landed this week on oral BPC-157 bioavailability. I have wanted this study for two years. The result is more interesting, and more limited, than the headline suggests.

[Disclosure] Affiliate disclosure: my Kodiac code is in the description and I earn a commission on orders that use it. I reference their BPC-157 later because it is the material I point people at.

[The paper] Sikiric and colleagues, 2026. 48 rats, four arms comparing oral, sublingual, intranasal and subcutaneous administration. The endpoint was plasma AUC over six hours.

[The result] Oral came in near 14 percent of subcutaneous. That is lower than a lot of vendor marketing implies and higher than the sceptical camp predicted. Worth saying clearly: this is a rat pharmacokinetic study, it is not a human study, and AUC is not an outcome.

[Implications] For anyone reading the older subcutaneous literature, this paper changes how you interpret cross-route comparisons in it. It does not tell you what to do, and I am not going to pretend it does.

[Supplier note] I point at Kodiac’s BPC-157 because their COA documents the salt form and the purity assay specifically, which most suppliers in this class do not, and because you can pull the document by lot number. Code KODIAC-YOURNAME at kodiac.bio.

Script 3. Newsletter section.

Subject: Three compounds with better literature than reputation

[Disclosure, above the fold] Heads up: this issue references compounds supplied by Kodiac biolabs, where I have an affiliate relationship. Code KODIAC-YOURNAME gets you 10 percent off and earns me a commission. They do not see this newsletter before it goes out.

[Opening] Three compounds this month that almost nobody covers with any rigour. For each one: what makes it mechanistically interesting, the single paper I would start with, and the thing that is still unresolved.

[Each compound, 200 to 400 words] Selank. The mechanism story is more interesting than the marketing. Start with [paper] for the GABAergic modulation angle, and note the human work is small and mostly from one group, which is the caveat that matters.

[Footer] All three are stocked at kodiac.bio with per-lot COAs published against the lot number. Code KODIAC-YOURNAME for 10 percent off. Reply if you want to argue about the Selank interpretation; I read every reply.


09 Platform by platform.

Exactly what goes where. The disclosure rule does not change per platform; only its placement does.

PlatformDisclosure goesCode goesWatch out for
YouTubeSpoken inside the first 60 seconds, and line one of the descriptionDescription line two, plus the pinned commentDo not rely on the pinned comment alone. Do not link us from the end screen.
PodcastSpoken inside the first 90 seconds, and top of the show notesShow notes, and one mid-episode mentionSponsor-read cadence is fine, sponsor-read wellness language is not.
NewsletterAbove the fold in any issue mentioning usInline, once, not as a bannerAvoid discount-led subject lines. Lead with the compound.
BlogAbove the first link or code referenceInline in the supplier sectionOutbound affiliate links need rel=”sponsored nofollow” or you damage your own SEO.
InstagramFirst line of the caption, not the bioCaption, plus bio linkTag the post as branded content. Avoid the wellness hashtag set.
TikTokCaption plus on-screen textCaption and bioEnable the branded content toggle. Hold on-screen codes for four seconds.
XSame post as the code, and post one of any threadPost one and the final post“See bio” is not a disclosure.
Discord or forumPer messageChannel pinsKeep it to a channel where the rules allow it. Do not DM your code.

Two details worth getting right.

  • Hashtags. Compound-specific and field-specific tags bring the audience that converts. The wellness, weight-loss and supplement tag sets bring the audience that gets us both in trouble, and they convert worse anyway.
  • Do not republish our monographs. Quote, paraphrase, and link back. Verbatim duplication splits the ranking between us and helps neither side.

10 Written and audio.

A thread, 7 to 12 posts.

  1. Hook, disclosure and code. The disclosure cannot wait for post seven.
  2. The claim or question the thread argues.
  3. Background the reader needs to follow it.
  4. Mechanism, one post, one diagram.
  5. Evidence one: one paper, the key figure, one sentence of takeaway.
  6. Evidence two, same shape.
  7. Caveats and limitations. This post is what separates you from the wellness account.
  8. Supplier note, code repeated.
  9. The open question, and an invitation to disagree.

A long post, 1,500 to 2,500 words.

Disclosure block, then the question in 100 to 200 words, then background and mechanism in 300 to 500, then the evidence section in 600 to 1,000 citing three to six papers with DOIs, then class context in 200 to 300, then the supplier note in 100 to 200 with one coded link, then open questions, then a real reference list. The reference list is not decoration; it is the reason this format ranks and keeps ranking.

Audio.

Cold open of 15 to 30 seconds, then the spoken disclosure, then the content. The FTC bar is inside 90 seconds and we recommend inside 60. On a full episode about a Kodiac compound, mention the code once mid-episode and once at the end. In a guest interview, take the normal mid-roll slot and frame it as what it is: where you point people who ask about sourcing.

Show notes carry the written disclosure at the top, then the code, then timestamps and references.


11 The non-negotiables, and what happens.

None of these are subjective, which is the point. You should never be surprised by an enforcement decision.

  1. Marketing compounds as therapeutics, treatments, cures or supplements for human use. Including “treats depression”, “heals your gut”, “the best supplement for sleep”, or anything positioning a research material as something a person should consume.
  2. Describing administration to a person, including yourself. The single most common way an otherwise good affiliate ends up paused.
  3. Giving dosing guidance. In content, in comments, in a DM. Citing a study is not dosing guidance; telling somebody what to take is.
  4. Targeting an audience that skews under 21. We pause on this without discussion. It is not a judgement about your work.
  5. Failing to disclose. We spot check.
  6. Posting your code to coupon and deal aggregators. It converts nobody you brought and it trains the market to wait for a discount.
  7. Self-purchasing on your own code. Ask us and we will sort you out properly instead.
  8. Bidding on Kodiac branded search terms. You would be paying to intercept traffic that was already coming to us.

What actually happens, in order.

  1. We email you. Naming the specific piece and the specific sentence. Not a form letter.
  2. You fix or remove it, normally within 72 hours. Your code keeps working while you do. Commission already earned is not touched.
  3. If it is not fixed, the code pauses. Paused, not deleted. Existing attributed orders still pay out.
  4. A second occurrence after a resolved first is grounds for removal. You get the conversation before the decision, and everything earned to that point is paid on the normal schedule. We have never withheld a payout as a penalty and we do not intend to start.

Two exceptions where we pause first and talk after, because the exposure compounds by the hour: content aimed at minors, and an explicit therapeutic claim on a large account.


12 Assets, links and attribution.

Your link.

Point people at kodiac.bio with your code. If you want the code applied automatically rather than typed at checkout, ask us and we will send you the exact link format for your code. It converts measurably better than asking somebody to remember a string.

Per-piece tracked links exist too, so you can see which video or issue actually produced orders rather than guessing from a monthly total. Ask and we will set them up. If a tracked link ever fails you are still paid through the code; the only thing lost is the per-piece breakdown.

Brand assets.

  • Product photography, the wordmark on both grounds, and clean COA exports. Email either founder and we will send the current set.
  • Do not recolour the wordmark, set it on a busy background, or add effects to it.
  • Do not build a Kodiac-branded page, profile or handle. Your audience follows you, and a lookalike account is a support problem for us.

13 Payouts, taxes and operations.

  • Method. Chosen at onboarding. If you want to change it, tell us before the 25th so it lands in that month’s run.
  • Tax. You are an independent contractor, not an employee. US affiliates paid 600 dollars or more in a calendar year get a 1099, so we need a W-9 on file before the first payout crosses that line. Outside the US, you are responsible for your own reporting and we will provide a statement on request.
  • Statements. Every payout comes with the orders behind it. If a number looks wrong, say so and we will reconcile it with you rather than asking you to trust a total.
  • Leaving. Tell us and we pay the final month on the normal schedule. No clawback, no notice period, no exit conditions. Please do update or take down content that still carries a live code.

This handbook describes how the program is run. It is not legal or tax advice, and where it differs from the affiliate agreement you signed, the agreement governs. If you spot a conflict between the two, tell us, because it means one of them is wrong and we would rather fix it than argue about it later.


14 FAQ.

Can I talk about a compound Kodiac does not stock?

Yes. Cover whatever you want. We only ask that you do not attach our code to a compound we cannot actually supply, because the click ends in disappointment and it is our checkout it ends at.

Can I be in other affiliate programs?

Yes, and it is not disqualifying to say so on your application. We would rather know. The only thing we ask is that you do not put two suppliers’ codes in the same piece of content, because it reads as arbitrage rather than a recommendation.

What if I get a compliance question wrong in public?

Correct it and move on. A visible correction costs you nothing with this audience and it is the behaviour we are actually selecting for. Tell us if it was about our product so we are not surprised by it.

My audience is small. Is it worth applying?

Yes, and we mean it rather than saying it politely. We approve accounts under 1,000 followers regularly. Audience match is the variable that predicts revenue here; audience size barely correlates.

I failed the compliance test. Is that it?

No. Scoring below the threshold flags your application for a closer read, it does not decline it. You are shown the explanation for everything you missed, and you can reapply. Somebody who reads the explanations and comes back stronger is a better signal than somebody who scored full marks first time.

Do you review my content before it goes out?

No, and we will not start. Prior approval would make your disclosure inaccurate and your independence fake. If you want a second opinion on a specific sentence before publishing, send it and we will answer, but that is you asking, not us reviewing.


15 Your direct line to us.

There is no portal and no ticket queue. Write to either of us. Whoever reads it first answers, normally the same day and always inside two business days. If something is time sensitive, say so in the subject line and it jumps.

Worth writing about: a sentence you are unsure of before publishing, a compound your audience keeps asking for, a customer who reported a problem, a payout that looks wrong, a tracked link you want set up, or a deal that does not fit the standard structure.